


**WHAT IS CLAIMED IS:**

1. A compound having the formula:



wherein

W and X are independently selected from the group consisting of N and CH;

Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl and (C<sub>2</sub>-C<sub>10</sub>)alkynyl;

Z is selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl and NR<sup>2</sup>R<sup>3</sup>;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C<sub>1</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl and perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl; and wherein when Z is NR<sup>2</sup>R<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> can be combined to form a 5- to 7-membered heterocyclyl ring;

R<sup>4</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;

A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system, said ring system being mono- or bicyclic wherein said mono- or bicyclic rings are selected from the group consisting of five- and six-membered rings that are aromatic or partially or completely saturated; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic or partially or completely saturated, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms, wherein the B ring substituents are selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl,

perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy.

2. A compound of claim 1, wherein W is N and X is CH.

3. A compound of claim 1, wherein W is N and X is N.

4. A compound of claim 1, wherein W is CH and X is N.

5. A compound of claim 1, wherein W is CH and X is CH.

6. A compound of claim 2, wherein Y is selected from the group consisting of O and S.


7. A compound of claim 2, wherein Y is O.

8. A compound of claim 2, wherein Y is S.


9. A compound of claim 2, wherein Z is NR<sup>2</sup>R<sup>3</sup>.

10. A compound of claim 6, wherein R<sup>4</sup> is H.

11. A compound of claim 1, wherein A is selected from the group consisting of:




12. A compound of claim 1, wherein A is selected from the group consisting of:



wherein

$R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are independently selected from the group consisting of H, halogen,  $CF_3$ ,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl,  $(C_1-C_6)$ heteroalkyl,  $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ thioalkoxy, amino,  $(C_1-C_6)$ alkylamino, di $(C_1-C_6)$ alkylamino,  $(C_3-C_{10})$ cycloalkyl,  $(C_4-C_{10})$ cycloalkyl-alkyl,  $(C_3-C_{10})$ cycloheteroalkyl,  $(C_3-C_{10})$ cycloheteroalkyl-alkyl, cyano, nitro,  $(C_1-C_6)$ acyl,  $(C_1-C_6)$ acylamino,  $(C_1-C_6)$ alkoxycarbonyl,  $(C_1-C_6)$ alkoxycarbonyl  $(C_1-C_6)$ alkyl,  $CONH_2$ ,  $CO-NH-(C_1-C_6)$ alkyl,  $CO-N[(C_1-C_6)alkyl]_2$ ,  $SO_2NH_2$ ,  $SO_2NH-(C_1-C_6)alkyl$ ,  $SO_2N-[(C_1-C_6)alkyl]_2$  and  $(C_1-C_6)$ heteroalkoxy; or two adjacent R groups selected from  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$ , can be linked together to form a new 5- or 6-membered carbocyclic or heterocyclic ring.

13. A compound of claim 12, wherein W is N; X is CH; Y is O or S; and A is selected from the group consisting of:



14. A compound of claim 1, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

15. A compound of claim 1, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

16. A compound of claim 1, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-

1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

**17.** A compound of claim 1, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.


**18.** A compound of claim 13, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

**19.** A compound of claim 13, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

**20.** A compound of claim 13, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

**21.** A compound of claim 13, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

**22.** A compound of claim 1, wherein W is N; X is CH; Y is O or S; Z is H, CH<sub>3</sub>, NH<sub>2</sub> or NHCH<sub>3</sub>; R<sup>1</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, or perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl; R<sup>4</sup> is H; A represents



wherein R<sup>6</sup> and R<sup>7</sup> are independently selected from the group consisting of H, halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, (C<sub>2</sub>-C<sub>4</sub>)alkynyl, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl and cyano; and B is a five-membered aromatic ring system containing at least one nitrogen atom.

**23.** A compound of claim 22, wherein Y is S.

1                    24.    A compound of claim 22, wherein Z is  $\text{NR}^2\text{R}^3$ .

1                    25.    A compound of claim 22, wherein Z is  $\text{NH}_2$ .

1                    26.    A compound of claim 22, wherein  $\text{R}^1$  is  $(\text{C}_1\text{-C}_6)\text{alkyl}$ ,  $(\text{C}_1\text{-C}_6)\text{heteroalkyl}$  or  $(\text{C}_3\text{-C}_{10})\text{cycloheteroalkyl-alkyl}$ .


1                    27.    A compound of claim 22, wherein B is a five-membered aromatic  
2 ring system containing 1-2 nitrogen atoms and 0-1 sulfur atoms.

1                    28.    A compound of claim 27, wherein B is unsubstituted or substituted  
2 by  $(\text{C}_1\text{-C}_3)\text{alkyl}$ ,  $\text{CF}_3$ , cyano, or halogen.

1                    29.    A compound of claim 22, wherein Z is  $\text{NH}_2$ ;  $\text{R}^6$  is selected from the  
2 group consisting of H, halogen,  $\text{CF}_3$ ,  $\text{CF}_3\text{O}$ ,  $(\text{C}_1\text{-C}_4)\text{alkyl}$ ,  $(\text{C}_2\text{-C}_4)\text{alkenyl}$ ,  $(\text{C}_1\text{-C}_4)\text{heteroalkyl}$ ,  $(\text{C}_3\text{-C}_{10})\text{cycloheteroalkyl-alkyl}$  and cyano, wherein the alkyl, alkenyl and  
3 heteroalkyl groups optionally bear additional substituents selected from cyano,  
4 heteroalkyl groups optionally bear additional substituents selected from cyano,  
5 carboxamido,  $(\text{C}_1\text{-C}_3)\text{alkylsulfonyl}$  or  $(\text{C}_1\text{-C}_3)\text{alkoxy}$ ; and  $\text{R}^7$  is selected from the group  
6 consisting of H, halogen,  $\text{CF}_3$ ,  $\text{CF}_3\text{O}$ ,  $(\text{C}_1\text{-C}_4)\text{alkyl}$ ,  $(\text{C}_2\text{-C}_4)\text{alkenyl}$ ,  $(\text{C}_2\text{-C}_4)\text{alkynyl}$ ,  $(\text{C}_1\text{-C}_4)\text{heteroalkyl}$  and cyano.  
7

1                    30.    A compound of claim 29, wherein  $\text{R}^6$  is selected from the group  
2 consisting of  $\text{CH}_2(\text{CH}_2)_m\text{CN}$ ,  $\text{CH}_2(\text{CH}_2)_n\text{SO}_2\text{CH}_3$  and  $\text{CH}_2(\text{CH}_2)_n\text{OCH}_3$ , wherein the  
3 subscript n is an integer from 0 to 2.


1                    31.    A compound of claim 29, wherein  $\text{R}^6$  is



1                    32.    A compound of claim 29, wherein  $\text{R}^7$  is selected from H, halogen,  
2  $\text{CF}_3$  and  $(\text{C}_1\text{-C}_4)\text{alkyl}$ .

1                    33.    A compound of claim 29, wherein  $\text{R}^7$  is methyl.

1                    34.    A compound of claim 1, having the formula:



wherein Y is O, S or N-CN; W' is N(CH<sub>3</sub>), N(CF<sub>3</sub>), N(CH<sub>2</sub>CH<sub>3</sub>), O or S; the subscripts n and n' are independently integers from 0 to 3; R<sup>7</sup> is H, halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, (C<sub>2</sub>-C<sub>4</sub>)alkynyl, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl or cyano; R<sup>9</sup> is CN, CONH<sub>2</sub>, CO-NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, CO-N[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>, CO-NH-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, CO-N[(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl]<sub>2</sub>, S(O)<sub>n''</sub>-(C<sub>1</sub>-C<sub>6</sub>)alkyl, S(O)<sub>n''</sub>-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, heteroaryl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>3</sub>-C<sub>6</sub>)cycloheteroalkyl, wherein each n'' is independently an integer of 0 to 2; R<sup>10</sup> is NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, N[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, N[(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, S(O)<sub>n''</sub>-(C<sub>1</sub>-C<sub>6</sub>)alkyl, S(O)<sub>n''</sub>-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, aryl, heteroaryl, O-(C<sub>1</sub>-C<sub>6</sub>)alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl or (C<sub>3</sub>-C<sub>8</sub>)cycloheteroalkyl; and R<sup>11</sup> is H, CF<sub>3</sub>, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, N[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>, halogen or (C<sub>1</sub>-C<sub>3</sub>)alkyl.

**35.** A compound of claim **34**, wherein Y is O or S; W' is N-CH<sub>3</sub>; n is 2; n' is 1-3; R<sup>9</sup> is cyano, CONH<sub>2</sub>, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>3</sub>-C<sub>6</sub>)cycloheteroalkyl; R<sup>10</sup> is NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, N[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, N[(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl]<sub>2</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>3</sub>-C<sub>8</sub>)cycloheteroalkyl; and R<sup>11</sup> is H.

**36.** A compound of claim **22**, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

**37.** A compound of claim **22**, wherein B contains a nitrogen atom at the point of attachment of B to the remainder of the molecule.

**38.** A compound of claim **22**, wherein B is selected from the group consisting of substituted or unsubstituted imidazolyl, substituted or unsubstituted thiazolyl and substituted or unsubstituted triazolyl.


**39.** A compound of claim **22**, wherein B is selected from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-













1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

40. A compound of claim 1, wherein Y is S; Z is NH<sub>2</sub> and R<sup>1</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl.

41. A compound of claim 40, wherein R<sup>1</sup> is methyl.

42. A compound of claim 1, wherein said compound is selected from the group consisting of:





and

4


5

1

2

43. A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:





wherein

W and X are independently selected from the group consisting of N and CH;

Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl and (C<sub>2</sub>-C<sub>10</sub>)alkynyl;

Z is selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl and NR<sup>2</sup>R<sup>3</sup>;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C<sub>2</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>2</sub>-C<sub>4</sub>)heteroalkyl, heteroaryl(C<sub>2</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>2</sub>-C<sub>4</sub>)heteroalkyl and perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl; and wherein when Z is NR<sup>2</sup>R<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> can be combined to form a 5- to 7-membered ring; and wherein when Y is N(R), R and R<sup>1</sup> are optionally combined to form a 5- to 7-membered ring;

R<sup>4</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;

A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system, said ring system being mono- or bicyclic wherein said mono- or bicyclic rings are selected from the group consisting of five- and six-membered rings that are aromatic or partially or completely saturated; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic or partially or completely saturated, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms, wherein the B ring substituents are selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl, perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-

C<sub>6</sub>alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy.

44. A composition in accordance with claim 43, wherein W is N and X is CH.

45. A composition in accordance with claim 43, wherein W is N and X is N.

46. A composition in accordance with claim 43, wherein W is CH and X is N.

47. A composition in accordance with claim 43, wherein W is CH and X is CH.

48. A composition in accordance with claim 43, wherein Y is selected from the group consisting of O and S.


49. A composition in accordance claim 43, wherein Y is O.

50. A composition in accordance claim 43, wherein Y is S.


51. A composition in accordance claim 43, wherein Z is NR<sup>2</sup>R<sup>3</sup>.

52. A composition in accordance with claim 48, wherein R<sup>4</sup> is H.

53. A composition in accordance with claim 43, wherein A is selected from the group consisting of:




54. A composition in accordance with claim 43, wherein A is selected from the group consisting of:



wherein

R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of H, halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, cyano, nitro, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>3</sub>-C<sub>6</sub>)alkoxycarbonylalkyl, CONH<sub>2</sub>, CO-NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, CO-N[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub> and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy; or two adjacent R groups can be linked together to form a new 5- or 6-membered carbocyclic or heterocyclic ring.

55. A composition in accordance with claim 43, wherein W is N; X is CH; Y is O or S; and A is selected from the group consisting of:



56. A composition in accordance with claim 43, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

1                   **57.**     A composition in accordance with claim **43**, wherein B contains a  
2     nitrogen atom at the point of attachment of B to the remainder of the molecule.

1                   **58.**     A composition in accordance with claim **43**, wherein B is selected  
2     from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-  
3     methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-  
4     methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

1                   **59.**     A composition in accordance with claim **43**, wherein B is selected  
2     from the group consisting of substituted or unsubstituted imidazolyl, substituted or  
3     unsubstituted thiazolyl and substituted or unsubstituted triazolyl.


1                   **60.**     A composition in accordance with claim **55**, wherein B contains a  
2     nitrogen atom at a position two atoms away from the atom attaching B to the remainder of  
3     the molecule.

1                   **61.**     A composition in accordance with claim **55**, wherein B contains a  
2     nitrogen atom at the point of attachment of B to the remainder of the molecule.

1                   **62.**     A composition in accordance with claim **55**, wherein B is selected  
2     from the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-  
3     methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-  
4     methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

1                   **63.**     A composition in accordance with claim **55**, wherein B is selected  
2     from the group consisting of substituted or unsubstituted imidazolyl, substituted or  
3     unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

1                   **64.**     A method for treating an inflammatory, metabolic or malignant  
2     condition, said method comprising administering to a subject in need of such treatment,  
3     an effective amount of a compound having the formula:



wherein

W and X are independently selected from the group consisting of N and CH;

Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO<sub>2</sub>, (C<sub>1</sub>-

C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-

C<sub>10</sub>)alkenyl and (C<sub>2</sub>-C<sub>10</sub>)alkynyl;

Z is selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl,

(C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl and NR<sup>2</sup>R<sup>3</sup>;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-

C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C<sub>2</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>3</sub>-

C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl,

(C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>2</sub>-C<sub>4</sub>)heteroalkyl,

heteroaryl(C<sub>2</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>2</sub>-C<sub>4</sub>)heteroalkyl and perfluoro(C<sub>1</sub>-

C<sub>6</sub>)alkyl; and wherein when Z is NR<sup>2</sup>R<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> can be combined to

form a 5- to 7-membered ring; and wherein when Y is N(R), R and R<sup>1</sup> are

optionally combined to form a 5- to 7-membered ring;

R<sup>4</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

(C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;

A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system,

said ring system being mono- or bicyclic wherein said mono- or bicyclic

rings are selected from the group consisting of five- and six-membered

rings that are aromatic or partially or completely saturated; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic or

partially or completely saturated, containing at least one nitrogen atom,

and from 0 to 3 additional heteroatoms, wherein the B ring substituents are

selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl,

perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl,

(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-

33 C<sub>6</sub>alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-  
 34 C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-  
 35 C<sub>6</sub>)acylamino, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-  
 36 C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy.

1 65. A method in accordance with claim 64, wherein W is N and X is  
 2 CH.

1 66. A method in accordance with claim 64, wherein W is N and X is N.

1 67. A method in accordance with claim 64, wherein W is CH and X is  
 2 N.

1 68. A method in accordance with claim 64, wherein W is CH and X is  
 2 CH.

1 69. A method in accordance with claim 65, wherein Y is selected from  
 2 the group consisting of O and S.


1 70. A method in accordance with claim 65, wherein Y is O.

1 71. A method in accordance with claim 65, wherein Y is S.


1 72. A method in accordance with claim 65, wherein Z is NR<sup>2</sup>R<sup>3</sup>.

1 73. A method in accordance with claim 69, wherein R<sup>4</sup> is H.

1 74. A method in accordance with claim 64, wherein A is selected from  
 2 the group consisting of:




75. A method in accordance with claim 64, wherein A is selected from the group consisting of:



wherein

R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of H, halogen, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, cyano, nitro, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>3</sub>-C<sub>6</sub>)alkoxycarbonylalkyl, CONH<sub>2</sub>, CO-NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, CO-N[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub> and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy; or two adjacent R groups can be linked together to form a new 5- or 6-membered carbocyclic or heterocyclic ring.

76. A method in accordance with claim 64, wherein W is N; X is CH; Y is O or S; and A is selected from the group consisting of:



77. A method in accordance with claim 64, wherein B contains a nitrogen atom at a position two atoms away from the atom attaching B to the remainder of the molecule.

1                   **78.**     A method in accordance with claim **64**, wherein B contains a  
2     nitrogen atom at the point of attachment of B to the remainder of the molecule.

1                   **79.**     A method in accordance with claim **64**, wherein B is selected from  
2     the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-  
3     methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-  
4     methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

1                   **80.**     A method in accordance with claim **64**, wherein B is selected from  
2     the group consisting of substituted or unsubstituted imidazolyl, substituted or  
3     unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

1                   **81.**     A method in accordance with claim **76**, wherein B contains a  
2     nitrogen atom at a position two atoms away from the atom attaching B to the remainder of  
3     the molecule.

1                   **82.**     A method in accordance with claim **76**, wherein B contains a  
2     nitrogen atom at the point of attachment of B to the remainder of the molecule.

1                   **83.**     A method in accordance with claim **76**, wherein B is selected from  
2     the group consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-  
3     methylimidazol-1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-  
4     methyl-1,3,4-triazolyl, and 4-methyl-1,2,4-triazol-3-yl.

1                   **84.**     A method in accordance with claim **76**, wherein B is selected from  
2     the group consisting of substituted or unsubstituted imidazolyl, substituted or  
3     unsubstituted thiazolyl and substituted or unsubstituted triazolyl.

1                   **85.**     A method in accordance with claim **64**, wherein said compound is  
2     administered orally.

1                   **86.**     A method in accordance with claim **64**, wherein said compound is  
2     administered topically.

1                   **87.**     A method in accordance with claim **64**, wherein said compound is  
2     administered intravenously or intramuscularly.




1                   88.     A method in accordance with claim 64, wherein said compound is  
2 administered in combination with a second therapeutic agent, said second therapeutic  
3 agent being a member selected from the group consisting of prednisone, dexamethasone,  
4 beclomethasone, methylprednisone, betamethasone, hydrocortisone, methotrexate,  
5 cyclosporin, rapamycin, tacrolimus, antihistamine drugs, TNF antibodies, IL-1 antibodies,  
6 soluble TNF receptors, soluble IL-1 receptors, TNF or IL-1 receptor antagonists, non-  
7 steroidal antiinflammatory agents, COX-2 inhibitors, antidiabetic agents, and anticancer  
8 agents.

1                   89.     A method in accordance with claim 88, wherein said administering  
2 is sequential.

1                   90.     A method in accordance with claim 64, wherein said inflammatory,  
2 metabolic or malignant condition is selected from the group consisting of rheumatoid  
3 arthritis, inflammatory bowel disease, psoriasis, cancer, diabetes and septic shock.

1                   91.     A method for treating a condition or disorder mediated by IKK,  
2 comprising  
3 administering to a subject in need thereof a therapeutically effective  
4 amount of a compound having the formula:



5  
6 wherein

7                   W and X are independently selected from the group consisting of N and CH;

8                   Y is selected from the group consisting of O, S and N(R);

9                   wherein R is selected from the group consisting of H, CN, NO<sub>2</sub>, (C<sub>1</sub>-

10                   C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-

11                   C<sub>10</sub>)alkenyl and (C<sub>2</sub>-C<sub>10</sub>)alkynyl;

12                   Z is selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl,

13                   (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl and NR<sup>2</sup>R<sup>3</sup>;


$R^1$ ,  $R^2$  and  $R^3$  are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C<sub>1</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl and perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl; and wherein when Z is NR<sup>2</sup>R<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> can be combined to form a 5- to 7-membered heterocyclyl ring;

$R^4$  is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;

A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system, said ring system being mono- or bicyclic wherein said mono- or bicyclic rings are selected from the group consisting of five- and six-membered rings that are aromatic or partially or completely saturated; and

B is a substituted or unsubstituted five- or six-membered ring which is aromatic or partially or completely saturated, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms, wherein the B ring substituents are selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl, perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy.

**92.** A method for modulating IKK, comprising contacting a cell with a compound having the formula:



wherein


W and X are independently selected from the group consisting of N and CH;

Y is selected from the group consisting of O, S and N(R);  
 wherein R is selected from the group consisting of H, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl and (C<sub>2</sub>-C<sub>10</sub>)alkynyl;  
 Z is selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl and NR<sup>2</sup>R<sup>3</sup>;  
 R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C<sub>1</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>4</sub>)heteroalkyl and perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl; and wherein when Z is NR<sup>2</sup>R<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> can be combined to form a 5- to 7-membered heterocyclyl ring;  
 R<sup>4</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;  
 A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system, said ring system being mono- or bicyclic wherein said mono- or bicyclic rings are selected from the group consisting of five- and six-membered rings that are aromatic or partially or completely saturated; and  
 B is a substituted or unsubstituted five- or six-membered ring which is aromatic or partially or completely saturated, containing at least one nitrogen atom, and from 0 to 3 additional heteroatoms, wherein the B ring substituents are selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl, perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-C<sub>6</sub>)acylamino, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy.

**93.** The method of Claim 92, wherein said compound is an IKK inhibitor.

3                    94.     The method of Claim 92, wherein said compound is an IKK  
4     activator.

1                    95.     A method for the preparation of antiinflammation agents  
2     comprising contacting a precursor compound having the formula:



3  
4     wherein


5     W and X are independently selected from the group consisting of N and CH;

6     R<sup>4</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
7     (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;

8     A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system,  
9     said ring system being mono- or bicyclic wherein said mono- or bicyclic  
10     rings are selected from the group consisting of five- and six-membered  
11     rings that are aromatic or partially or completely saturated; and

12     B is a substituted or unsubstituted five- or six-membered ring which is aromatic or  
13     partially or completely saturated, containing at least one nitrogen atom,  
14     and from 0 to 3 additional heteroatoms, wherein the B ring substituents are  
15     selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl,  
16     perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl,  
17     (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-  
18     C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-  
19     C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-  
20     C<sub>6</sub>)acylamino, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-  
21     C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy

22     with a compound having the formula:



23  
24     wherein


25     Y is selected from the group consisting of O, S and N(R);

wherein R is selected from the group consisting of H, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl and (C<sub>2</sub>-C<sub>10</sub>)alkynyl;

Z is selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl and NR<sup>2</sup>R<sup>3</sup>;


R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)alkenyl, (C<sub>2</sub>-C<sub>10</sub>)alkynyl, (C<sub>2</sub>-C<sub>10</sub>)heteroalkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl-alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloheteroalkyl, aryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, aryl(C<sub>2</sub>-C<sub>4</sub>)heteroalkyl, heteroaryl(C<sub>2</sub>-C<sub>4</sub>)alkyl, heteroaryl(C<sub>2</sub>-C<sub>4</sub>)heteroalkyl and perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl; and wherein when Z is NR<sup>2</sup>R<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> can be combined to form a 5- to 7-membered ring; and wherein when Y is N(R), R and R<sup>1</sup> are optionally combined to form a 5- to 7-membered ring;

under conditions sufficient to produce compounds having the formula:



wherein each of A, B, R<sup>1</sup>, R<sup>4</sup>, W, X, Y and Z have the meanings provided above.

96. A compound having the formula:



wherein

W and X are independently selected from the group consisting of N and CH;

R<sup>4</sup> is selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl-alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl;

A is a substituted or unsubstituted fused carbocyclic or heterocyclic ring system, said ring system being mono- or bicyclic wherein said mono- or bicyclic

rings are selected from the group consisting of five- and six-membered  
 rings that are aromatic or partially or completely saturated; and  
 B is a substituted or unsubstituted five- or six-membered ring which is aromatic or  
 partially or completely saturated, containing at least one nitrogen atom,  
 and from 0 to 3 additional heteroatoms, wherein the B ring substituents are  
 selected from the group consisting of halogen, CF<sub>3</sub>, CF<sub>3</sub>O, (C<sub>1</sub>-C<sub>6</sub>)alkyl,  
 perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl,  
 (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)thioalkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-  
 C<sub>6</sub>)alkylamino, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>4</sub>-C<sub>10</sub>)cycloalkyl-alkyl, (C<sub>3</sub>-  
 C<sub>10</sub>)cycloheteroalkyl, cyano, nitro, sulfonamido, (C<sub>1</sub>-C<sub>6</sub>)acyl, (C<sub>1</sub>-  
 C<sub>6</sub>)acylamino, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>2</sub>-C<sub>6</sub>)alkoxycarbonyl(C<sub>1</sub>-  
 C<sub>6</sub>)alkyl, carboxamido and (C<sub>1</sub>-C<sub>6</sub>)heteroalkoxy.

97. A compound of claim 96, wherein R<sup>4</sup> is hydrogen.

98. A compound of claim 96, wherein R<sup>4</sup> is hydrogen, Y is O or S, and  
 Z is NR<sup>2</sup>R<sup>3</sup>.

99. A compound of claim 96, wherein R<sup>4</sup> is hydrogen, Y is O or S, Z is  
 NR<sup>2</sup>R<sup>3</sup>, and B contains a nitrogen atom at a position two atoms away from the atom  
 attaching B to the remainder of the molecule.

100. A compound of claim 96, B contains a nitrogen atom at the point of  
 attachment of B to the remainder of the molecule.

101. A compound of claim 99, wherein B is selected from the group  
 consisting of 1-methylimidazol-5-yl, 1-(trifluoromethyl)imidazol-5-yl, 5-methylimidazol-  
 1-yl, 5-(trifluoromethyl)imidazol-1-yl, thiazol-5-yl, imidazol-1-yl, 1-methyl-1,3,4-  
 triazolyl, and 4-methyl-1,2,4-triazol-3-yl.